Othera Pharmaceuticals Inc., a privately-held specialty pharmaceutical company
developing proprietary drugs to treat or prevent the three leading causes of blindness,
announced today that it has appointed Al Reaves, Ph.D., as Senior Vice President
of Clinical Development. Dr. Al Reaves has 22 consecutive years of ophthalmology
drug development experience. During his career, he has been responsible for bringing
numerous ophthalmic products to market, and previously, led the Visudyne global
clinical development program at Novartis and worked with the Genentech/Novartis
partnership for Lucentis approval in Europe.